[1]李惠敏,吴惠华,孟庆霞,等.抗苗勒管激素在IVF治疗多囊卵巢综合征患者中的应用价值探讨[J].南京师范大学学报(自然科学版),2018,41(01):88.[doi:10.3969/j.issn.1001-4616.2018.01.016]
　Li Huimin,Wu Huihua,Meng Qingxia,et al.To Investigate the Value of Anti-Müllerian Hormone in Patientswith Polycystic Ovary Syndrome During in vitro Fertilization[J].Journal of Nanjing Normal University(Natural Science Edition),2018,41(01):88.[doi:10.3969/j.issn.1001-4616.2018.01.016]
点击复制

抗苗勒管激素在IVF治疗多囊卵巢综合征患者中的应用价值探讨()
分享到：

《南京师范大学学报》（自然科学版）[ISSN:1001-4616/CN:32-1239/N]

卷:
第41卷
期数:
2018年01期
页码:
88
栏目:
·生命科学·
出版日期:
2018-03-31

文章信息/Info

Title:
To Investigate the Value of Anti-Müllerian Hormone in Patientswith Polycystic Ovary Syndrome During in vitro Fertilization
文章编号:
1001-4616(2018)01-0088-09
作者:
李惠敏; 吴惠华; 孟庆霞; 邹琴燕; 李建芬; 王 玮; 李 红
南京医科大学附属苏州医院,苏州市立医院,生殖与遗传中心,江苏 苏州 215002
Author(s):
Li Huimin; Wu Huihua; Meng Qingxia; Zou Qinyan; Li Jianfen; Wang Wei; Li Hong
Center of Reproduction and Genetics,The Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Suzhou 215002,China
关键词:
体外授精-胚胎移植; 多囊卵巢综合征; 卵泡液; 抗苗勒氏管激素
Keywords:
in vitro fertilization-embryo transfer; polycystic ovary syndrome; follicular fluid; anti-Müllerian hormone
分类号:
R711.6
DOI:
10.3969/j.issn.1001-4616.2018.01.016
文献标志码:
A
摘要:
比较体外授精-胚胎移植(in vitro fertilization-embryo transfer,IVF-ET)治疗中多囊卵巢综合征(polycystic ovary syndrome,PCOS)患者与非PCOS患者基础血清及卵泡液抗苗勒管激素(anti-müllerian hormone,AMH)水平; 分析AMH与PCOS患者的临床特征、IVF结局的关系; 进一步探讨AMH在IVF治疗PCOS患者中的应用价值. 回顾性分析2010年8月至2012年6月本生殖中心行IVF-ET 治疗的69
Abstract:
To compare serum basal and follicular fluid levels of AMH in patients with PCOS and non-PCOS that in the treatment of IVF-ET; analyze the relationship of AMH with clinical characteristics and IVF outcomes of patients with PCOS; further to investigate the value of AMH in patients with PCOS during IVF treatment. A retrospective analysis was performed on patients accepted IVF-ET treatment in our center from August 2010 to June 2012,who were divided into two groups,69 PCOS patients and 95 non-PCOS patients with normal ovulation to analysis the basal serum and follicular fluid AMH levels and IVF outcomes between the two groups. The results showed that,(1)Levels of serum AMH,LH,T,LH/FSH ratio,AFC,BMI and the total number of retrieved oocytes in PCOS group were significantly higher than these of control group(P<0.05).(2)In control group,the serum AMH level has a significantly positive correlation with AFC,the total number of retrieved oocytes and the number of mature eggs(P<0.05),but it has a negative correlation with age(P<0.05); in PCOS group,the serum AMH level has a significantly positive correlation with AFC(P<0.05),but no correlation was found with the total number of retrieved oocytes,the number of mature eggs and age(P>0.05). The serum AMH level has a negative correlation with Gonadotropin dosage in both groups(P<0.05).(3)Levels serum of AMH and follicular fluid have a significantly positive correlation(P<0.05). The AMH level in follicular fluid of normal fertilized oocytes was lower than that of abnormal fertilized oocytes in PCOS group,no difference was found in follicular fluid AMH level between normal and abnormal fertilized oocytes in control group,but follicular fluid AMH level of normal fertilized oocytes in control group was lower than that of PCOS group(P<0.05).(4)No correlation was found between follicular fluid AMH level and corresponding embryo quality in both PCOS and controls(P>0.05). The basal serum AMH level in PCOS patients has a strong correlation with the AFC. A relatively low initial dose of Gonadotropin has an important clinical significance in reducing the incidence of OHSS and obtaining an ideal number of oocytes in PCOS patients with high basal serum AMH and AFC. In addition,the elevated follicular fluid AMH level might affect the potential development of oocyte and its normal fertilization,thus,providing a new marker to predict the oocyte normal fertilization. While the levels of AMH in follicular fluid could not predict the embryo quality and clinical pregnancy outcome.

参考文献/References:

[1] RAJPERT D M E,JORGENSEN N,GRAEM N,et al. Expression of anti-Müllerian hormone during normal and pathological gonadal development:association with differentiation of Sertoli and granulosa cells[J]. Journal of clinical endocrinology and metabolism,1999,84(10):3 836-3 844.
[2]WEENEN C,LAVEN J S,VON BERGH A R,et al. Anti-Müllerian hormone expression pattern in the human ovary:potential implications for initial and cyclic follicle recruitment[J]. Mol Hum Reprod,2004,10:77-83.
[3]DURLINGER A L,VISSER J A,THEMMEN A P,et al. Regulation of ovarian function:the role of anti-Müllerian hormone[J]. Reproduction,2002,124(5):601-609.
[4]DIAMANTI K E,KOULI C,TSIANATELI T,et al. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome[J]. Eur J Endocrinol,1998,138(3):269-274.
[5]PIGNY P,JONARD S,ROBERT Y,et al. Serum anti-Müllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.[J]. J Clin Endocrinol Metab,2006,91(3):941-945.
[6]LAVEN J S,MULDERS A G,VISSER J A,et al. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age[J]. J Clin Endocrinol Metab,2004,89(1):318-323.
[7]PILTONEN T,MORIN P L,KOIVUNEN R,et al. Serum Anti-mullerrian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome[J]. Hum Reprod,2005,20(7):1 820-1 826.
[8]FALLAT M E,SIOW Y,MARRA M,et al. Mullerian-inhibiting substance in follicular fluid and serum:a comparison of patients with tubal factor infertility,polycystic ovary syndrome,and endometriosis[J]. Fertil Steril,1997,67(5):962-965.
[9]DAS M,GILLOTT D J,SARIDOGAN E,et al. Anti-Müllerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome[J]. Hum Reprod,2008,23:2122-26.
[10]DEWAILLY D,GRONIER H,PONCELET E,et al. Diagnosis of polycystic ovary syndrome(PCOS):revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries[J]. Hum Reprod,2011,26(11):3 123-3 129.
[11]MORAN L J,NOAKES M,CLIFTON P M,et al. The use of anti-Müllerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab,2007,92(10):3796-802.
[12]MCGEE E A,HSUEH A J. Initial and cyclic recruitment of ovarian follicles[J]. Endocr Rev,2000,2l(2):200-214.
[13]DURLINGER A L,KRAMER P,KARELS B,et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary[J]. Endocrinology,1999,140(12):5 789-5 796.
[14]DURLINGER A L,GRUIJTERS M J,KARELS B,et al. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary[J]. Endocrinology,2002,143(3):1 076-1 084.
[15]CARLSSON I B,SCOTT JE,VISSER J A,et al. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro[J]. Hum Reprod,2006,21(9):2 223-2 227.
[16]La MARCA A,ORVIETO R,GIULINI S,et al. Müllerian-inhibiting substance in women with polycystic ovary syndrome:relationship with hormonal and metabolic characteristics[J]. Fertil Steril,2004,82(4):970-972.
[17]PELLATT L,HANNA L,BRINCAT M,et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries[J]. Clin Endocrinol Metab,2007,92(1):240-245.
[18]MCLLVEEN M,SKULL J D,LEDGER W L. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population[J]. Hum Reprod,2007,22(3):778-785.
[19]TSEPELIDIS S,DEMEESTERE I,DELBAERE A. Anti-Müllerian hormone and its role in the regulation of ovarian function[J]. Rev Med Brux,2007,28(3):165-171.
[20]VISSER J A,de JONG F,LAVEN J S,et al. Anti-mullerrian hormone:a new marker for ovarian function[J]. Reproduction,2006,131(1):1-9.
[21]van ROOIJ I A,BROEKMANS F J,SCHEFFER G J. Serum anti-Müllerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility:a longitudinal study[J]. Fertil Steril,2005,83(4):979-987.
[22]RIGS R M,DURAN E H,BAKER M W,et al. Assessment of ovarian reserve with anti-Müllerian hormone:a comparison of the predictive value of anti-Müllerian hormone,follicle-Stimulating hormone,inhibin B,and age[J]. Am J Obstet Cynecol,2008,199(2):202.e1-8.
[23]La MARCA A,SIGHINOLFI G,RADI D,et al. Anti-Müllerian hormone(AMH)as a predictive marker in assisted reproductive technology(ART)[J]. Hum Reprod Update,2010,16(2):113-130.
[24]NAKHUDA G S,CHU M C,WANG J G,et al. Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization[J]. Fertil Steril,2006,85(5):1 541-1 543.
[25]LEE T H,LIU C H,HUANG C C,et al. Serum anti-Müllerian hormone and estradiol leveIs as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles[J]. Hum Reprod,2008,23(1):160-167.
[26]HAZOUT A,BOUCHARD P,SEIFER D B,et al. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone,inhibin B,or estradiol[J]. Fertil Steril,2004,82(5):1 323-1 329.
[27]SOMAYEH A,GHAMARTAJ H,BATOOL H R. Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome[J]. Ann Saudi Med,2010,30(6):442-447.
[28]EBNER T,SOMMERGRUBER M,MOSER M,et al. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles[J]. Hum Reprod,2006,21(8):2 022-2 026.
[29]TAKAHASHI C,FUJITO A,KAZUKA M,et al. Anti-Müllerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization[J]. Fertil Steril,2008,89(3):586-591.
[30]FANCHIN R,MENDEZ LOZANO D H,FRYDMAN N,et al. Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization[J]. J Clin Endocrinol Metab,2007,92(5):1 796-1 802.
[31]PABUCCU R,KAYA C,CAAGˇLAR G S,et al. Follicular-fluid anti-Müllerian hormone concentrations are predictive of assisted reproduction outcome in PCOS patients[J]. Reprod Biomed Online,2009,19(5):631-637.
[32]CUPISTI S,DITTRICH R,MUELLER A,et al. Correlations between anti-Müllerian hormone,inhibin B,and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes[J]. Eur J Med Res,2007,12(12):604-608.
[33]DESFORGES B V,GALLO C,LEFEBVRE C,et al. Increased anti-Müllerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization[J]. Fertil Steril,2010,94(1):198-204.
[34]YILMAZ N,UYGUR D,DOGAN M,et al. The effect of follicular anti-Müllerian hormone levels of non-obese,non-hyperandrogenemic polycystic ovary syndrome patients on assisted reproduction outcome[J]. Gynecol Endocrinol,2012,28(3):162-165.

备注/Memo

备注/Memo:
收稿日期:2017-09-30.
基金项目:苏州市临床医学中心(SXXZ201505)、江苏省妇幼健康重点人才(FRC201725).
通讯联系人:李红,主任医师,博导,研究方向:生殖医学的临床与基础研究. E-mail:hongliszivf@163.com
更新日期/Last Update: 2018-03-31